12 Best Performing Healthcare Stocks to Buy Right Now

3. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Number of Hedge Fund Holders: 58 

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading biotech company specializing in RNA interference (RNAi) therapeutics, is advancing treatments for rare and prevalent diseases, notably transthyretin amyloidosis (ATTR). Its flagship product, Amvuttra (vutrisiran), treats both hereditary and cardiomyopathy forms of ATTR.

In Q2 2025, Amvuttra sales surged to $492 million, surpassing the $350 million consensus, driven by expanded use for ATTR cardiomyopathy approved in March 2025. Approximately 1,400 patients were on therapy by the end of the quarter. Strong performance prompted ALNY to raise its 2025 revenue guidance for Amvuttra and Onpattro to $2.18–$2.28 billion, with total projected net revenues between $2.65–$2.8 billion. This growth has lifted the company’s market valuation above $50 billion, with shares up over 15% recently.

Amvuttra’s quarterly subcutaneous administration may enhance patient adherence compared to oral competitors like Pfizer’s tafamidis and BridgeBio’s Attruby. Priced at $476,000 annually for cardiomyopathy, it is increasingly used as a first-line therapy, with commercial and Medicare payers approving treatment without prior competitor use, supporting sustainable growth in the U.S. market.

Beyond commercial success, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is advancing its pipeline, including RNAi therapeutics for cardiovascular disease, such as zilebesiran for hypertension. The business also presented 12-month HELIOS-B Phase 3 data showing sustained benefits of Amvuttra in ATTR cardiomyopathy. Additionally, ALNY joined the Alliance for Genomic Discovery in September 2025, leveraging large-scale genomic datasets to accelerate target discovery and innovation in gene silencing therapies.